Drugs and patents in ATC class H05A - PARATHYROID HORMONES AND ANALOGUES

Last updated: June 15, 2026

ATC H05A (parathyroid hormones and analogues) is dominated commercially by a small set of branded products that are largely protected by a mix of compound, formulation, and method-of-use patents, plus regulatory exclusivity (where applicable). In practice, market entry risk concentrates around (i) expiry of active-ingredient and composition-of-matter patents for teriparatide and PTH analogs, (ii) device and injection-formulation IP, and (iii) clinical-data and exclusivity constraints for any entrants relying on FDA 505(b)(2) or abbreviated pathways for closely related “same active moiety” products.

The patent landscape is not uniform across the ATC class. Some sub-franchises (notably teriparatide) have moved into late-life stages where branded exclusivity has already largely cleared, leaving only incremental IP (device, formulation, dosing regimen) and any late-expiring secondary patents as barriers. Other sub-franchises (notably newer PTH analogs with distinct structures or dosing systems) retain active primary and secondary patent estates that continue to constrain true generic competition and may channel competitors toward biosimilar-like strategies only if the regulatory classification and reference product construct support it.

Which products define ATC H05A market dynamics and patent risk?

Featured products in ATC H05A include:

Teriparatide (PTH 1-34; recombinant human parathyroid hormone analog)
Abaloparatide (PTHrP analog)
PTH(1-84) and related parathyroid hormone analogs used for hypoparathyroidism, depending on geography
Calcimimetic combinations and vitamin D analogs are typically outside H05A (ATC segregation matters in competitive mapping)

Market dynamic pattern:

Osteoporosis dominates demand for PTH-based therapies (especially as second-line options following antiresorptives).
Hypoparathyroidism is the second demand pillar and tends to be treated with longer duration, which sustains formulation and dosing IP importance.
Switching costs are high due to titration protocols, fracture-risk stratification, and prescriber familiarity with specific devices and injection regimens.

What patents protect teriparatide (PTH 1-34) and its delivery system?

Executive answer: Teriparatide protection historically comes from compound and composition-of-matter patents, then narrows toward formulation-specific patents and device/injection-regimen patents. The strongest residual risk to entrants is typically device and ready-to-use formulation claims (stability, concentration, excipients) and method-of-use claims tied to fracture-risk outcomes.

What formulation IP issues block teriparatide “true generic” launches?

Concentration and fill-volume definitions in prefilled injection devices
Stabilizing excipient systems and pH windows that preserve peptide integrity
Manufacturing controls that maintain shelf-life and reduce aggregation
Device claims if the formulation is inseparable from the delivery system as claimed

What method-of-use claims matter in litigation and licensing?

Treatment of osteoporosis in high fracture-risk populations
Dosing regimens (daily dosing schedules; duration limits)
Combination or sequencing claims relative to antiresorptives (where present)

How “authorized vs. generic” entry usually plays out

True generics face the tightest scrutiny where the reference product uses a distinct device and formulation system.
505(b)(2)-style entrants often compete on formulation/dosing differences while attempting to avoid infringement of method-of-use and formulation claims.

When does teriparatide lose exclusivity and what launch timing risks exist?

Executive answer: For teriparatide, the practical exclusivity timeline is driven less by remaining primary patent coverage (often earlier in the life cycle) and more by late-expiring formulation and secondary-use patents, plus any Hatch-Waxman litigation that can trigger stays.

Timing risk map (typical for late-life products):

Patent expiration triggers the earliest possible legal launch, but
Paragraph IV litigation can delay FDA approval/marketing for up to statutory stay periods, then
Last-man-standing can occur if some patents remain in force against at least one Orange Book-listed claim set.

What patents protect abaloparatide and how does the estate differ from teriparatide?

Executive answer: Abaloparatide’s patent estate tends to emphasize the distinct active ingredient structure (primary compound coverage) and then secondary patents around dosing regimen and formulation/device performance.

What patent categories create the highest entry barrier for abaloparatide?

Active-ingredient composition-of-matter
Formulation composition and stability claims
Dosing regimen or patient-population method-of-use claims
Delivery system performance claims if device integration is claimed

What generic entry risks exist if entrants try to “design around”?

“Design around” is often feasible at the formulation level but less so for method-of-use claims if the labeling and therapeutic regimen match the reference.
Device-based workarounds do not eliminate formulation- and stability-related infringement risk.

How do FDA regulatory pathways change patent strategy across ATC H05A?

Executive answer: Patent strategy tracks regulatory pathway selection.

Common US pathway outcomes

If the reference product qualifies for an ANDA as a small-molecule generic (when legally eligible), entrants focus on “same active ingredient” and then address formulation/device and Orange Book-listed patents via Paragraph IV.
If no ANDA eligibility exists, entrants typically pivot to 505(b)(2), which increases reliance on literature/bridging data and does not eliminate the need to clear method-of-use and formulation IP.

Exclusivity vs patent expiration

Even after patent expiration, clinical and labeling exclusivity can shape market timing. In ATC H05A, the binding constraint for challengers is usually IP rather than purely regulatory exclusivity.

What is the Orange Book status of ATC H05A products, and how does it affect Paragraph IV challenges?

Executive answer: Orange Book status determines whether an ANDA can trigger a patent dispute under Hatch-Waxman. For ATC H05A products, patent lists typically include multiple claim types: formulation, method-of-use, and sometimes device-adjacent claims.

How challengers structure Paragraph IV

File ANDA with Paragraph IV certifications against each Orange Book-listed patent
Prepare claim-by-claim noninfringement/invalidity positions, usually strongest against:
- specific formulation parameters (if claims are parameterized),
- narrow method-of-use limitations (if labeling differs),
- or obviousness over peptide formulation prior art where the record supports it.

How settlement affects market entry

Settlements often convert into:
- agreed “launch carve-out” dates,
- territorial or product-form differences,
- dismissal of infringement claims in exchange for payment and/or covenant not to sue.

Which companies are challenging H05A patents and what does that imply for future generic entry?

Executive answer: Patent challenges in ATC H05A typically come from a mix of established US generic manufacturers and global players that have peptide formulation capabilities and device manufacturing experience.

Business implication: The winners are those that can clear:

formulation stability requirements,
device integration,
and the tightest method-of-use claim sets via labeling design and claim construction.

What patent litigation affects ATC H05A commercialization?

Executive answer: For H05A, litigation risk is concentrated on the remaining Orange Book patents closest to expiration. Where multiple patents are listed, challengers often face “last patent standing” effects. Settlements reduce uncertainty and lock in launch dates, especially for products with multiple secondary patents.

Litigation patterns that matter

Multiple patents per NDA, leading to serial stays
Claim construction fights around formulation parameters
Narrow method-of-use disputes tied to labeling language

What formulations are protected by ATC H05A patents?

Executive answer: Across H05A, the most litigated formulation themes include peptide stabilization and ready-to-use performance:

pH and buffer system constraints
stabilizer excipients and concentration windows
aggregation control and shelf-life performance
adsorption control in prefilled syringe components

Why this matters for entrants: It forces formulators to replicate not just pharmacokinetics but the stability profile relevant to claim parameters.

How strong is the patent estate for parathyroid hormone analogs versus generic entry barriers?

Executive answer: Patent strength is product-specific:

Teriparatide typically shows a “shrinking moat” toward the end of the life cycle, where remaining barriers are mostly secondary patents and device/formulation details.
Abaloparatide generally retains a broader moat into later periods due to distinct active ingredient coverage plus regimen/formulation IP.

Practical ranking (qualitative):

Highest remaining risk: products with active composition-of-matter and regimen-formulation coupling
Medium risk: products where composition-of-matter has expired but device/formulation and method-of-use claims persist
Lower risk: products where most Orange Book-listed patents are expired and only narrow secondary claims remain

What generic entry risks exist across H05A, and what scenarios drive delays?

Executive answer: Generic entry risk is driven by litigation stays and “late list” patents. Key scenarios:

Paragraph IV litigation + last patent standing delays FDA approval even after some patents expire.
Adverse final court outcomes can prevent approval or force design changes.
Settlement agreements can shift the “effective launch date” far beyond earliest statutory launch.

How does ATC H05A commercialization compare across teriparatide and abaloparatide?

Executive answer: The competitive dynamic is less about purely cost and more about:

patient eligibility criteria (fracture risk thresholds),
prescriber familiarity,
and device/formulation substitution acceptance.

Patent estate impact:

Teriparatide’s late-life environment tends to make price competition possible sooner once remaining secondary patents clear.
Abaloparatide’s estate often pushes competitors toward later-time launches or settlements.

What manufacturing/IP barriers matter most for PTH analogs?

Executive answer: PTH analogs are sensitive peptides where formulation and manufacturing controls are a major IP and regulatory barrier.

Manufacturing elements that affect infringement and approval

Process controls for peptide integrity and aggregation profiles
Fill-finish steps that impact adsorption and stability
Device-syringe compatibility validated against claimed formulation parameters

Why generic manufacturability affects patent strategy

Entrants may be able to noninfringe formulation claims by changing excipients, but those changes can trigger new regulatory demands and can still land the product within method-of-use claims if labeling is unchanged.

Key patent and exclusivity decision checklist for investors and BD in H05A

Identify the Orange Book patent families by claim type (composition, formulation, method-of-use).
Map the litigation posture of each family (pending Paragraph IV, stayed approvals, settlement dates).
Model launch timing under last-patent-standing rather than simple earliest expiration.
Evaluate device/formulation substitution feasibility given peptide stability and claim parameterization.
Use labeling design as an IP strategy where method-of-use claims are the main threat.

Key Takeaways

ATC H05A market dynamics are concentrated in a small number of PTH-based osteoporosis and hypoparathyroidism therapies, with competition shaped by late-life formulation/device and method-of-use patents.
Teriparatide typically trends toward a narrower residual moat late in its lifecycle, while abaloparatide often retains a broader active ingredient plus regimen/formulation barrier deeper into the exclusivity period.
The practical “when can a generic launch” answer is driven by Orange Book patent lists, Paragraph IV litigation stays, and settlement-driven effective launch dates, not just primary patent expiry.
For entrants, the binding constraints are peptide formulation stability, device compatibility, and method-of-use claim avoidance through labeling and claim-construction strategy.

FAQs

Which claim types in the Orange Book for PTH analogs most often block generic approval under Paragraph IV?
Does a device redesign alone avoid infringement for PTH analog formulation patents?
What labeling changes most effectively reduce method-of-use infringement risk for osteoporosis PTH therapies?
How do settlement agreements in Hatch-Waxman cases usually affect “effective” launch dates for H05A products?
Are PTH analogs in ATC H05A generally more vulnerable to delayed generic entry due to formulation stability IP or due to method-of-use claims?

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
U.S. Food and Drug Administration. Drug Approval Reports and related regulatory pathway information for approved products. FDA.
United States Court and Federal Circuit decisions related to Hatch-Waxman patent disputes (Hatch-Waxman litigation reporting).

Drugs in ATC Class H05A

Subclasses in ATC: H05A - PARATHYROID HORMONES AND ANALOGUES

Market dynamics and patent landscape for ATC H05A (parathyroid hormones and analogues): who owns exclusivity and what generics/biosimilars can enter when?